Journal Article10.1111/J.1600-065X.2007.00551.X
Dendritic cell subsets in health and disease.
Hideki Ueno,Eynav Klechevsky,Eynav Klechevsky,Rimpei Morita,Caroline Aspord,Tinghua Cao,Toshimichi Matsui,Tiziana Di Pucchio,John E. Connolly,Joseph W. Fay,Virginia Pascual,A. Karolina Palucka,Jacques Banchereau +12 more
462
TL;DR: It is proposed that interstitial (dermal) DCs preferentially activate humoral immunity, whereas Langerhans cells preferential induce cellular immunity.
read more
Abstract: The dendritic cell (DC) system of antigen-presenting cells controls immunity and tolerance. DCs initiate and regulate immune responses in a manner that depends on signals they receive from microbes and their cellular environment. They allow the immune system to make qualitatively distinct responses against different microbial infections. DCs are composed of subsets that express different microbial receptors and express different surface molecules and cytokines. Our studies lead us to propose that interstitial (dermal) DCs preferentially activate humoral immunity, whereas Langerhans cells preferentially induce cellular immunity. Alterations of the DC system result in diseases such as autoimmunity, allergy, and cancer. Conversely, DCs can be exploited for vaccination, and novel vaccines that directly target DCs in vivo are being designed.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Cancer immunotherapy via dendritic cells
TL;DR: Dendritic cells are an essential target in efforts to generate therapeutic immunity against cancer owing to their ability to control both immune tolerance and immunity.
1.9K
Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells
TL;DR: New developments in the understanding of the biology of LCs and other langerin+ DCs are described and the challenges that remain in identifying the role of different DC subsets in tissue immunity are discussed.
860
Alopecia areata update: Part I. Clinical picture, histopathology, and pathogenesis
Abdullah Alkhalifah,Adel Alsantali,Eddy Hsi Chun Wang,Kevin J. McElwee,Jerry Shapiro,Jerry Shapiro +5 more
TL;DR: Part one of this two-part series on AA describes the clinical presentation and the associated histopathologic picture and proposes a hypothesis for AA development based on the most recent knowledge of disease pathogenesis.
743
Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines
TL;DR: This Review deals with recent progress in the immunotherapy of established (pre)malignant disease of viral or non-viral origin by synthetic vaccines capable of inducing robust T-cell responses.
617
Dendritic cells and cytokines in human inflammatory and autoimmune diseases.
TL;DR: Targeting these cytokines with biological agents as already is the case with TNF and IL-1 represents a success of immunology and the coming years will expand the range of cytokines as therapeutic targets in autoinflammatory and autoimmune pathology.
570
References
Of mice and not men: differences between mouse and human immunology
TL;DR: Known discrepancies in both innate and adaptive immunity are outlined, including balance of leukocyte subsets, defensins, Toll receptors, inducible NO synthase, the NK inhibitory receptor families Ly49 and KIR, FcR, Ig subsets andChemokine and chemokine receptor expression.
3.6K
Tolerogenic dendritic cells.
TL;DR: It is suggested that several clinical situations, including autoimmunity and certain infectious diseases, can be influenced by the antigen-specific tolerogenic role of DCs.
3.2K
Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells.
Frank O. Nestle,Selma Alijagic,Michel Gilliet,Yuansheng Sun,Stephan Grabbe,Reinhard Dummer,Günter Burg,Dirk Schadendorf +7 more
TL;DR: Vaccination with autologous DCs generated from peripheral blood is a safe and promising approach in the treatment of metastatic melanoma and antigen-specific immunity was induced during DC vaccination.
3K
The three Es of cancer immunoediting.
TL;DR: The history of the cancer immunosurveillance controversy is summarized and its resolution and evolution into the three Es of cancer immunoediting--elimination, equilibrium, and escape are discussed.
3K